Roche’s Actemra (Tocilizumab) Fails to Meet Endpoints in REMDACTA Trial Targeting COVID-19 Pneumonia

Roche’s Actemra (Tocilizumab) Fails to Meet Endpoints in REMDACTA Trial Targeting COVID-19 Pneumonia

Although some studies have evidenced to the contrary, the anti-inflammatory drug called Actemra combined with Veklury (remdesivir) did not lead to reduced hospitalization as has been determined with via data from the REMDACTA trial, which looked at the cocktail only remdesivir and standard of care. Moreover, the clinical trial revealed that the Actemra-remdesivir combination failed to achieve secondary targets, such as failing to reduce the probability that a patient would need support from mechanical ventilation or reducing the mortality rate. Roche’s Levi Garraway declared, “Given the global impact of COVID-19 pneumonia on patients, we are disappointed that the REMDACTA study did not meet its endpoints.” While Roche is on the record that the “totality of the data” involving their drug encompassing results from, other data evidences the drug can help at least select patients. Mixed study results lead to varied responses from various medicinal evidence bodies: in some countries, ACTEMRA is embraced for at least select conditions associated with COVID-19 while in other nations, the door is shut. Germany is an example of the latter where the Association of Medical Societies recommen...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee